SCHEMBL17828775

SCHEMBL17828775

Fc1ccc(-c2nc(-c3cccc(-n4c5ccccc5c5ccc(-n6c7ccccc7c7ccccc76)cc54)c3)c3ccc4ccccc4c3n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP1B1 Q16678 3/20 0.37
KDM4E B2RXH2 3/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
MTOR P42345 1/20 0.33
DPP4 P27487 2/20 0.33
GRM2 Q14416 1/20 0.32
NR3C1 P04150 1/20 0.32
ATM Q13315 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ABCG2 Q9UNQ0 2/20 0.32
GRIA1 P42261 1/20 0.32
CACNG8 Q8WXS5 1/20 0.32
CACNG2 Q9Y698 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17828752 0.95 CYP1A1 (0.36) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828777 0.92 PIK3CA (0.36) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828776 0.92 PIK3CA (0.37) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828725 0.90 PIK3CA (0.37) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828979 0.89 ATM (0.39) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828746 0.89 NR3C1 (0.39) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828755 0.88 CYP1A2 (0.33) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828890 0.88 L3MBTL1 (0.37) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828839 0.88 L3MBTL1 (0.37) CYP1A1CYP1A2CYP1B1KDM4EMAPT
SCHEMBL17828806 0.88 L3MBTL1 (0.39) CYP1A1CYP1A2CYP1B1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME L1CAM, LEF1, EML4 CYP1A1 829/4885CYP1A2 1870/4885CYP1B1 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.